DRUG at a glance
BRIGHT MINDS BIOSCIENCES INC. (DRUG, SEC CIK 1827401) filed Form 4 insider filings as recently as April 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 19 institutional investment managers tracked by SignalX reported holding BRIGHT MINDS BIOSCIENCES INC. (DRUG) shares worth $94.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cormorant Asset Management, LP on April 28, 2026 of 109,331 shares at $89.50 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 19 funds
- $94.6M · +2 vs prior quarter
SignalX for DRUG
Don't miss the next DRUG filing
- Alerts as it files. A push when DRUG files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DRUG, by share count.
- Ask anything. An AI agent that reads every DRUG filing and answers with sources.
DRUG alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cormorant Asset Management, LP | Sell | Apr 28, 2026 | 109,331 | $89.50 |
| Cormorant Asset Management, LP | Sell | Apr 28, 2026 | 109,331 | $89.50 |
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DRUG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 19 | $94.6M |
| Q1 2026 | 17 | $87.9M |
| Q4 2025 | 17 | $75.6M |
| Q3 2025 | 16 | $42.2M |
| Q2 2025 | 12 | $15.2M |
| Q1 2025 | 6 | $13.8M |
| Q4 2024 | 2 | $1.5M |
- BlackRock+64.3K (+10%)
- Goldman Sachs Group+59.3K (+80%)
- Vanguard Portfolio Management LLC+19.6K (+32%)
- State Street Corp+13.9K (+13%)
- Millennium Management+13.9K (+26%)
- Morgan Stanley−114.2K (-86%)
- Ameriprise Financial−12.1K (-24%)
- Invesco Ltd−2.3K (-36%)
- Citadel Advisors LLC+66.5K
- Two Sigma Investments+9.6K
- Franklin Resources+8.0K
- D.E. Shaw & Co−15.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 89 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DRUG SEC filings: frequently asked questions
Which institutions hold DRUG stock?
As of June 30, 2026, the largest BRIGHT MINDS BIOSCIENCES INC. (DRUG) holders among the 13F filers tracked by SignalX were BlackRock ($48.2 million), Goldman Sachs Group ($9.4 million), State Street Corp ($8.6 million), Vanguard Portfolio Management LLC ($5.6 million), Millennium Management ($4.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest DRUG SEC filings?
BRIGHT MINDS BIOSCIENCES INC. (DRUG) filed a Form 4 insider filing on April 30, 2026.
What is DRUG's SEC CIK number?
BRIGHT MINDS BIOSCIENCES INC. (DRUG)'s SEC Central Index Key (CIK) is 1827401. EDGAR lists every DRUG filing under that number.
Ask anything about DRUG
The research agent reads DRUG's filings, financials, insider trades and 13F holders, then answers with sources.